Patients with heart failure with preserved ejection fraction have a equally high risk for
mortality and re-hospitalization as those with reduced ejection fraction. Effective
management strategies are critically needed to be established for this type of heart failure.
These patients have more hypertensive and ischemic etiology than those with reduced ejection
fraction. The investigators hypothesis is that Ca channel blocker nifedipine can improve the
heart failure clinical composite response endpoint compared with the conventional treatment
in patients with heart failure with hypertension and/or coronary artery disease and preserved
ejection fraction (>=50%) by echocardiography. This study is multi-center, prospective,
randomized, open-label, and blinded-endpoint design.